Comparison of the effectiveness of sirolimus- and paclitaxel-eluting stents for small coronary artery lesions

Kyoung Ha Park, Seong Wook Park, Myeongki Hong, Young Hak Kim, Bong Ki Lee, Duk Woo Park, Bong Ryong Choi, Mi Jeong Kim, Kyoung Min Park, Cheol Whan Lee, Sang Sig Cheong, Jae Joong Kim, Seung Jung Park

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background: The sirolimus-eluting stent (SES) and the paclitaxel-eluting stent (PES) reduce restenosis in small coronary artery lesions. However, it is not clear which of these stents is superior in terms of clinical outcomes. Methods: The authors retrospectively examined 197 patients with 245 de novo small coronary artery lesions (≤2.75 mm) that were treated with either the SES (156 lesions) or the PES (89 lesions). Six-month angiographic restenosis rates and the 9-month target lesion revascularization (TLR) rates were compared between the two groups. Results: In terms of baseline clinical and angiographic parameters, the two groups well matched together. Six-month angiographie follow-up was performed on 170 patients (86.3%), comprising 135 SES lesions (86.5%) and 76 PES lesions (85.4%). At 6-month angiographic follow-up, the late lumen loss was less in the SES group than in the PES group (0.29 ± 0.42 vs. 0.69 ± 0.63 mm, P < 0.01). Therefore, the SES group showed a lower rate of angiographic restenosis than the PES group (6.7% vs. 27.7%, P < 0.01). At 9 months there were no deaths or myocardial infarctions in either group. The 9-month TLR rate was lower in the SES group than in the PES group (3.3% vs. 14.4%, P < 0.01). The Kaplan-Meier estimate of freedom from TLR at 9 months was 96.7% for the SES patients and 86.5% for the PES patients (P < 0.01). Conclusions: The SES treatment may be superior to the PES treatment in terms of long-term clinical and angiographic outcomes in patients with small coronary artery lesions.

Original languageEnglish
Pages (from-to)589-594
Number of pages6
JournalCatheterization and Cardiovascular Interventions
Volume67
Issue number4
DOIs
Publication statusPublished - 2006 Apr 1

Fingerprint

Sirolimus
Paclitaxel
Stents
Coronary Vessels
Kaplan-Meier Estimate

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

Park, Kyoung Ha ; Park, Seong Wook ; Hong, Myeongki ; Kim, Young Hak ; Lee, Bong Ki ; Park, Duk Woo ; Choi, Bong Ryong ; Kim, Mi Jeong ; Park, Kyoung Min ; Lee, Cheol Whan ; Cheong, Sang Sig ; Kim, Jae Joong ; Park, Seung Jung. / Comparison of the effectiveness of sirolimus- and paclitaxel-eluting stents for small coronary artery lesions. In: Catheterization and Cardiovascular Interventions. 2006 ; Vol. 67, No. 4. pp. 589-594.
@article{1a07f4d7a57a4955869d9e17d2b24ba4,
title = "Comparison of the effectiveness of sirolimus- and paclitaxel-eluting stents for small coronary artery lesions",
abstract = "Background: The sirolimus-eluting stent (SES) and the paclitaxel-eluting stent (PES) reduce restenosis in small coronary artery lesions. However, it is not clear which of these stents is superior in terms of clinical outcomes. Methods: The authors retrospectively examined 197 patients with 245 de novo small coronary artery lesions (≤2.75 mm) that were treated with either the SES (156 lesions) or the PES (89 lesions). Six-month angiographic restenosis rates and the 9-month target lesion revascularization (TLR) rates were compared between the two groups. Results: In terms of baseline clinical and angiographic parameters, the two groups well matched together. Six-month angiographie follow-up was performed on 170 patients (86.3{\%}), comprising 135 SES lesions (86.5{\%}) and 76 PES lesions (85.4{\%}). At 6-month angiographic follow-up, the late lumen loss was less in the SES group than in the PES group (0.29 ± 0.42 vs. 0.69 ± 0.63 mm, P < 0.01). Therefore, the SES group showed a lower rate of angiographic restenosis than the PES group (6.7{\%} vs. 27.7{\%}, P < 0.01). At 9 months there were no deaths or myocardial infarctions in either group. The 9-month TLR rate was lower in the SES group than in the PES group (3.3{\%} vs. 14.4{\%}, P < 0.01). The Kaplan-Meier estimate of freedom from TLR at 9 months was 96.7{\%} for the SES patients and 86.5{\%} for the PES patients (P < 0.01). Conclusions: The SES treatment may be superior to the PES treatment in terms of long-term clinical and angiographic outcomes in patients with small coronary artery lesions.",
author = "Park, {Kyoung Ha} and Park, {Seong Wook} and Myeongki Hong and Kim, {Young Hak} and Lee, {Bong Ki} and Park, {Duk Woo} and Choi, {Bong Ryong} and Kim, {Mi Jeong} and Park, {Kyoung Min} and Lee, {Cheol Whan} and Cheong, {Sang Sig} and Kim, {Jae Joong} and Park, {Seung Jung}",
year = "2006",
month = "4",
day = "1",
doi = "10.1002/ccd.20700",
language = "English",
volume = "67",
pages = "589--594",
journal = "Catheterization and Cardiovascular Interventions",
issn = "1522-1946",
publisher = "Wiley-Liss Inc.",
number = "4",

}

Park, KH, Park, SW, Hong, M, Kim, YH, Lee, BK, Park, DW, Choi, BR, Kim, MJ, Park, KM, Lee, CW, Cheong, SS, Kim, JJ & Park, SJ 2006, 'Comparison of the effectiveness of sirolimus- and paclitaxel-eluting stents for small coronary artery lesions', Catheterization and Cardiovascular Interventions, vol. 67, no. 4, pp. 589-594. https://doi.org/10.1002/ccd.20700

Comparison of the effectiveness of sirolimus- and paclitaxel-eluting stents for small coronary artery lesions. / Park, Kyoung Ha; Park, Seong Wook; Hong, Myeongki; Kim, Young Hak; Lee, Bong Ki; Park, Duk Woo; Choi, Bong Ryong; Kim, Mi Jeong; Park, Kyoung Min; Lee, Cheol Whan; Cheong, Sang Sig; Kim, Jae Joong; Park, Seung Jung.

In: Catheterization and Cardiovascular Interventions, Vol. 67, No. 4, 01.04.2006, p. 589-594.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparison of the effectiveness of sirolimus- and paclitaxel-eluting stents for small coronary artery lesions

AU - Park, Kyoung Ha

AU - Park, Seong Wook

AU - Hong, Myeongki

AU - Kim, Young Hak

AU - Lee, Bong Ki

AU - Park, Duk Woo

AU - Choi, Bong Ryong

AU - Kim, Mi Jeong

AU - Park, Kyoung Min

AU - Lee, Cheol Whan

AU - Cheong, Sang Sig

AU - Kim, Jae Joong

AU - Park, Seung Jung

PY - 2006/4/1

Y1 - 2006/4/1

N2 - Background: The sirolimus-eluting stent (SES) and the paclitaxel-eluting stent (PES) reduce restenosis in small coronary artery lesions. However, it is not clear which of these stents is superior in terms of clinical outcomes. Methods: The authors retrospectively examined 197 patients with 245 de novo small coronary artery lesions (≤2.75 mm) that were treated with either the SES (156 lesions) or the PES (89 lesions). Six-month angiographic restenosis rates and the 9-month target lesion revascularization (TLR) rates were compared between the two groups. Results: In terms of baseline clinical and angiographic parameters, the two groups well matched together. Six-month angiographie follow-up was performed on 170 patients (86.3%), comprising 135 SES lesions (86.5%) and 76 PES lesions (85.4%). At 6-month angiographic follow-up, the late lumen loss was less in the SES group than in the PES group (0.29 ± 0.42 vs. 0.69 ± 0.63 mm, P < 0.01). Therefore, the SES group showed a lower rate of angiographic restenosis than the PES group (6.7% vs. 27.7%, P < 0.01). At 9 months there were no deaths or myocardial infarctions in either group. The 9-month TLR rate was lower in the SES group than in the PES group (3.3% vs. 14.4%, P < 0.01). The Kaplan-Meier estimate of freedom from TLR at 9 months was 96.7% for the SES patients and 86.5% for the PES patients (P < 0.01). Conclusions: The SES treatment may be superior to the PES treatment in terms of long-term clinical and angiographic outcomes in patients with small coronary artery lesions.

AB - Background: The sirolimus-eluting stent (SES) and the paclitaxel-eluting stent (PES) reduce restenosis in small coronary artery lesions. However, it is not clear which of these stents is superior in terms of clinical outcomes. Methods: The authors retrospectively examined 197 patients with 245 de novo small coronary artery lesions (≤2.75 mm) that were treated with either the SES (156 lesions) or the PES (89 lesions). Six-month angiographic restenosis rates and the 9-month target lesion revascularization (TLR) rates were compared between the two groups. Results: In terms of baseline clinical and angiographic parameters, the two groups well matched together. Six-month angiographie follow-up was performed on 170 patients (86.3%), comprising 135 SES lesions (86.5%) and 76 PES lesions (85.4%). At 6-month angiographic follow-up, the late lumen loss was less in the SES group than in the PES group (0.29 ± 0.42 vs. 0.69 ± 0.63 mm, P < 0.01). Therefore, the SES group showed a lower rate of angiographic restenosis than the PES group (6.7% vs. 27.7%, P < 0.01). At 9 months there were no deaths or myocardial infarctions in either group. The 9-month TLR rate was lower in the SES group than in the PES group (3.3% vs. 14.4%, P < 0.01). The Kaplan-Meier estimate of freedom from TLR at 9 months was 96.7% for the SES patients and 86.5% for the PES patients (P < 0.01). Conclusions: The SES treatment may be superior to the PES treatment in terms of long-term clinical and angiographic outcomes in patients with small coronary artery lesions.

UR - http://www.scopus.com/inward/record.url?scp=33646037329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646037329&partnerID=8YFLogxK

U2 - 10.1002/ccd.20700

DO - 10.1002/ccd.20700

M3 - Article

VL - 67

SP - 589

EP - 594

JO - Catheterization and Cardiovascular Interventions

JF - Catheterization and Cardiovascular Interventions

SN - 1522-1946

IS - 4

ER -